Dassault Systèmes (Euronext Paris: #13065, DSY.PA) hosted “The World After: From Things to Life 2020,” a one-of-a-kind virtual conference that provided in-depth insights into the vast potential of the life sciences industry in India. With a deep understanding of the current challenges facing pharmaceutical, biotech and medical device companies, and the patient care sector, Dassault Systèmes hosted the event as part of its commitment to help advance the pace of discovery of new drugs and medicines and deliver holistic, superior patient and physician-centric experiences.
“The World After – From Things to Life” focused on transforming and digitalizing the life sciences industry in India, which is undergoing core shifts in business processes and manufacturing operations to make it more agile and adaptable, reinventing the value chain, capitalizing knowledge and strategic planning, adhering to regulatory frameworks, and introducing futuristic and advanced technological solutions.
Addressing the business challenges of the life sciences industry, Dassault Systèmes demonstrated the “License to Cure for Biopharma,” “ONE Lab,” and “Accelerated Device” industry solution experiences based on the 3DEXPERIENCE platform. In the tracks of the virtual event, several global and local life sciences industry experts and startups shared their experiences.
The pharma segment of the event covered topics like digital continuity in the pharmaceutical industry, revolutionizing the drug development process with artificial intelligence, design and development of SARS-CoV-2 main protease inhibitors, optimizing laboratories and leveraging knowledge to improve time to market. Pharma and biopharma companies are moving towards unified platforms that help in drug research and discovery enhancing the ecosystem- research, development, manufacturing and quality and compliance. “Dassault Systèmes’ solution for quality control labs greatly reduced data input, transcription, and integrity validation efforts increased the overall productivity of the lab,” said Ashok Nayak, CIO, IPCA Laboratories.
The patient care segment in the event discussed “In-Silico in healthcare,” optimizing efficacy and safety for medical devices, simulation-driven new product development (NPD), simulation for understanding the functional dynamics of the brain and therapeutic stimulations using AI. The patient care sector is changing rapidly with a focus on improving patient outcomes and a shift from intermittent treatments to a continuous engagement driven by simulation technologies. “Multiphysics simulation capabilities have helped in the indigenous research and development of minimally invasive coronary stent systems as well as in maximizing their life and performance,” said Dr. Ramanan Lakshminarayanan, Chief Technology Officer, Sahajanand Medical Technologies.
The medical devices segment in the event highlighted faster time to market of innovative medical devices, and key technology solutions adopted in the diagnostics segment. Medical device manufacturers are moving away from point solutions for mechanical and electrical design, simulation, product data management (PDM) and technical communication, and toward integrated product development platforms to introduce product faster into the market and improve the overall performance and reliability, which is always the big challenge for them. “Medical Device manufacturers have to embrace digital technology to overcome the challenges in the manufacturing, product delivery, supply chain etc., which used to be an option in the past; now it is a must to sustain in the market and be innovative,” said Vishwaprasad Alva, Managing Director, Skanray.
“The World After – From Things to Life” also featured the 3DEXPERIENCE playground, which showcased innovations on industry-leading brands like SOLIDWORKS, BIOVIA and SIMULIA with virtual experiences and technology demos of the internet of things, artificial intelligence, machine leaning and data analytics applicable in the life sciences industry.
“We intend to be a catalyst and technology enabler behind all the new opportunities evolving in the life sciences industry in India,” said Deepak NG, Managing Director, India, Dassault Systemes. “We are born out of science and expertise in engineering. We want to bridge medical science and engineering into the domains of manufacturing of medical devices, to offering scientific applications on the 3DEXPERIENCE platform for drug research, discovery and manufacturing, to simulating treatments. Earlier this year, Dassault Systèmes announced its strategic direction for the coming years, extending its focus from things to life. We want to transform how people are cured and help them live a better life.”